Hologic, Inc. (HOLX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hologic, Inc. (HOLX) trades at $75.69 with AI Score 58/100 (Hold). Hologic, Inc. is a medical technology company focused on women's health. They develop, manufacture, and supply diagnostics, medical imaging systems, and surgical products. Market cap: 17B, Sector: Healthcare.
Last analyzed: Feb 8, 2026Hologic, Inc. (HOLX) Healthcare & Pipeline Overview
Hologic is a leading medical technology innovator dedicated to women's health, offering comprehensive solutions in diagnostics, breast health, GYN surgical, and skeletal health, driving growth through early detection and minimally invasive treatments with a strong global presence and a P/E ratio of 30.87.
Investment Thesis
Hologic presents a notable research candidate based on its leadership position in women's health and its diversified portfolio of diagnostic, imaging, and surgical solutions. The company's focus on early detection and minimally invasive treatments aligns with growing healthcare trends. Hologic's strong gross margin of 52.8% indicates pricing power and efficient operations. Key growth catalysts include the expansion of its molecular diagnostics offerings, particularly in infectious disease testing, and the increasing adoption of its 3D mammography systems. The company's established global presence and strategic partnerships further enhance its growth prospects. With a P/E ratio of 30.87, Hologic's valuation reflects its growth potential and market leadership. Investors may want to evaluate Hologic for its long-term growth prospects and commitment to women's health.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $16.70 billion, reflecting its significant presence in the medical technology sector.
- P/E ratio of 30.87, indicating investor confidence in future earnings growth.
- Profit margin of 13.2%, demonstrating efficient operations and profitability.
- Gross margin of 52.8%, showcasing strong pricing power and cost management.
- Beta of 0.73, suggesting lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Strong market position in women's health.
- Diversified product portfolio.
- Innovative technologies.
- Established global presence.
Weaknesses
- Dependence on specific product lines.
- Exposure to regulatory changes.
- Competition from larger medical device companies.
- Potential for product recalls.
Catalysts
- Continued adoption of 3D mammography for breast cancer screening.
- Expansion of molecular diagnostics offerings for infectious diseases.
- Potential regulatory approvals for new products and indications.
- Strategic partnerships and acquisitions to expand product portfolio.
Risks
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
- Pricing pressures from healthcare providers.
- Increased competition from new entrants.
- Product recalls or safety concerns.
Growth Opportunities
- Expansion of Molecular Diagnostics: Hologic can capitalize on the growing demand for molecular diagnostics by expanding its Aptima assay portfolio and developing new tests for infectious diseases and other conditions. The global molecular diagnostics market is projected to reach $15.5 billion by 2027, offering significant growth potential. Hologic's established Panther platform provides a competitive advantage in this market.
- Increased Adoption of 3D Mammography: Hologic is poised to benefit from the increasing adoption of 3D mammography for breast cancer screening. Studies have shown that 3D mammography improves detection rates and reduces false positives compared to traditional 2D mammography. The global 3D mammography market is expected to grow as healthcare providers invest in advanced imaging technologies. Hologic's leadership in breast imaging positions it well to capture this growth.
- Growth in GYN Surgical Solutions: Hologic's GYN Surgical segment offers opportunities for growth through the continued adoption of its NovaSure and MyoSure systems. These minimally invasive procedures provide effective treatment options for abnormal uterine bleeding and uterine fibroids. The market for minimally invasive gynecological procedures is growing as patients seek less invasive alternatives to traditional surgery. Hologic's innovative technologies and strong clinical evidence support its growth in this area.
- Strategic Partnerships and Acquisitions: Hologic can pursue strategic partnerships and acquisitions to expand its product portfolio, enter new markets, and enhance its technological capabilities. Collaborations with other healthcare companies and research institutions can accelerate innovation and drive growth. Targeted acquisitions can provide access to complementary technologies and expand Hologic's customer base. This will allow Hologic to continue to innovate and grow its market share.
- International Expansion: Hologic has opportunities to expand its presence in international markets, particularly in developing countries where healthcare infrastructure is improving and demand for advanced medical technologies is growing. By establishing distribution networks and partnerships in these regions, Hologic can increase its global reach and diversify its revenue streams. This will allow Hologic to tap into new markets and drive long-term growth.
Opportunities
- Expansion into emerging markets.
- Development of new diagnostic and treatment solutions.
- Strategic partnerships and acquisitions.
- Increased adoption of minimally invasive procedures.
Threats
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
- Pricing pressures from healthcare providers.
- Increased competition from new entrants.
Competitive Advantages
- Strong brand reputation in women's health.
- Extensive portfolio of patented technologies.
- Established relationships with healthcare providers.
- High switching costs for customers due to regulatory requirements and training.
About HOLX
Hologic, Inc., founded in 1985 and headquartered in Marlborough, Massachusetts, is a global leader in developing, manufacturing, and supplying innovative healthcare solutions primarily focused on women's health. The company operates through four key segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Hologic's Diagnostics segment offers a range of molecular diagnostic assays, including the Aptima platform for infectious disease detection and viral load testing for HIV, Hepatitis C, and Hepatitis B. Their portfolio also includes the ThinPrep System for cytology applications and tests for Group B Streptococcus. In Breast Health, Hologic provides advanced imaging and analytics, such as 2D and 3D digital mammography systems, biopsy guidance systems, and ultrasound solutions. The GYN Surgical segment features the NovaSure Endometrial Ablation System for abnormal uterine bleeding and the MyoSure Hysteroscopic Tissue Removal System for removing fibroids and polyps. The Skeletal Health segment offers the Horizon DXA system for bone densitometry and the Fluoroscan Insight FD mini C-arm for minimally invasive orthopedic procedures. Hologic sells its products through direct sales and service teams, as well as independent distributors, reaching customers across the United States, Europe, the Asia-Pacific region, and other international markets. With a market capitalization of $16.70 billion and a profit margin of 13.2%, Hologic is committed to advancing women's health through early detection and effective treatment.
What They Do
- Develops and manufactures diagnostic products for women's health.
- Offers medical imaging systems, including mammography and ultrasound.
- Provides surgical products for gynecological procedures.
- Offers molecular diagnostic assays for infectious disease detection.
- Provides systems for cytology applications.
- Offers products for skeletal health assessment.
Business Model
- Develops and manufactures medical devices and diagnostic assays.
- Sells products through direct sales and distributors.
- Generates revenue from product sales and service contracts.
- Invests in research and development to innovate new products.
Industry Context
Hologic operates in the medical instruments and supplies industry, which is characterized by technological innovation, stringent regulatory requirements, and increasing demand for advanced diagnostic and treatment solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and growing awareness of early detection and preventive care. Hologic competes with companies like CNC (Centene Corporation), COO (CooperCompanies), FMS (Fresenius Medical Care), ILMN (Illumina), and MEDP (Medpace Holdings), each with its own strengths and focus areas. Hologic's focus on women's health and its diversified product portfolio position it favorably in this competitive landscape.
Key Customers
- Hospitals and clinics
- Diagnostic laboratories
- Physician offices
- Research institutions
Financials
Chart & Info
Hologic, Inc. (HOLX) stock price: $75.69 (+0.17, +0.23%)
Latest News
-
BC-Most Active Stocks
Associated Press · Apr 6, 2026
-
Is Hologic Stock Outperforming the Dow?
Yahoo! Finance: HOLX News · Mar 18, 2026
-
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?
zacks.com · Mar 18, 2026
-
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates
businesswire.com · Mar 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HOLX.
Price Targets
Wall Street price target analysis for HOLX.
MoonshotScore
What does this score mean?
The MoonshotScore rates HOLX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
BC-Most Active Stocks
Is Hologic Stock Outperforming the Dow?
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates
What Investors Ask About Hologic, Inc. (HOLX) — Healthcare
What does Hologic, Inc. do?
Hologic, Inc. is a medical technology company focused on women's health. It develops, manufactures, and supplies a range of diagnostic products, medical imaging systems, and surgical products. Their offerings include molecular diagnostic assays for infectious diseases, breast imaging systems, GYN surgical solutions, and skeletal health assessment tools. Hologic's products are used by hospitals, clinics, laboratories, and physician offices worldwide to improve the early detection and treatment of various conditions, particularly those affecting women's health.
Is HOLX stock worth researching?
HOLX stock presents a mixed investment outlook. The company's strong market position in women's health and diversified product portfolio are positive factors. A gross margin of 52.8% demonstrates pricing power. However, a P/E ratio of 30.87 suggests a premium valuation. Investors may want to evaluate Hologic's growth catalysts, such as the expansion of molecular diagnostics and increased adoption of 3D mammography, while also assessing potential risks, such as economic downturns and technological obsolescence. A thorough analysis of Hologic's financial performance and industry trends is essential before making an investment decision.
What are the main risks for HOLX?
Hologic faces several risks, including economic downturns that could reduce healthcare spending, technological obsolescence that could render its products outdated, and pricing pressures from healthcare providers that could erode profit margins. Increased competition from existing and new market entrants also poses a threat. Additionally, Hologic is subject to regulatory changes and the potential for product recalls or safety concerns, which could negatively impact its financial performance and reputation. Investors should carefully consider these risks before investing in HOLX.
What are the key factors to evaluate for HOLX?
Hologic, Inc. (HOLX) currently holds an AI score of 58/100, indicating moderate score. The stock trades at a P/E of 31.2x, near the S&P 500 average (~20-25x). Key strength: Strong market position in women's health. Primary risk to monitor: Economic downturns affecting healthcare spending. This is not financial advice.
How frequently does HOLX data refresh on this page?
HOLX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HOLX's recent stock price performance?
Recent price movement in Hologic, Inc. (HOLX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in women's health. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HOLX overvalued or undervalued right now?
Determining whether Hologic, Inc. (HOLX) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 31.2. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HOLX?
Before investing in Hologic, Inc. (HOLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update. Financial data based on available information as of 2026-02-08.